Working… Menu

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02413580
Recruitment Status : Completed
First Posted : April 10, 2015
Last Update Posted : October 5, 2018
Information provided by (Responsible Party):
Grifols Therapeutics LLC

Brief Summary:
This is a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.

Condition or disease Intervention/treatment Phase
Myasthenia Gravis Exacerbations Biological: IGIV-C Phase 3

Detailed Description:
The study consists of a single dose course of IGIV-C treatment followed by 28-days of post-infusion assessments. The total duration of study participation for each subject is up to 28 ± 2 days. Approximately 50 subjects, ages 18 or greater, are planned to be enrolled in the study and receive a single, total dose of 2 g/kg of IGIV-C over 2 consecutive days (dose of 1 g/kg per day) across multiple centers in Argentina, Canada, Europe and South Africa.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations
Study Start Date : March 2015
Actual Primary Completion Date : April 2018
Actual Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: IGIV-C Treatment
An IV dose of 2 g/kg of IGIV-C will be administered in subjects with myasthenia gravis exacerbations.
Biological: IGIV-C
an IV dose of 2 g/kg of IGIV-C will be administered as 2 doses of 1 g/kg on two consecutive days

Primary Outcome Measures :
  1. Change in quantitative myasthenia gravis (QMG) scale score [ Time Frame: From Baseline (Day 0) to Day 14 ]

Secondary Outcome Measures :
  1. Percentage of subjects with clinical improvement assessed by QMG [ Time Frame: Baseline (Day 0) to Day 14 ]
  2. Percentage of subjects with clinical improvement assessed by MG-Activities of Daily Living (MG-ADL) [ Time Frame: Baseline (Day 0) to Day 14 ]
  3. Percentage of subjects with clinical improvement assessed by the MG Composite [ Time Frame: Baseline (Day 0) to Day 14 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be willing and able to provide written informed consent (if applicable, a legally authorized representative may provide informed consent on behalf of the subject).
  • Subjects who meet the clinical criteria for diagnosis of MG with an exacerbation defined as worsening of MG symptoms as defined by an Myasthenia Gravis Foundation of America (MGFA) classification IVb or V.
  • Subjects on long-term (8 weeks) corticosteroid treatment for MG.
  • Female subjects of child-bearing potential must have a negative test for pregnancy (human chorionic gonadotropin [HCG-based assay]).
  • Subjects must be willing to comply with all aspects of the clinical trial protocol, including blood sampling and long-term storage of extra samples, for the entire duration of the study.

Exclusion Criteria:

  • Subjects who have received immune globulin treatment given by IV, subcutaneous or intramuscular route within the last 30 days.
  • Subjects with documentation of a lack of clinical response to intravenous immunoglobulin (IVIg) therapy for MG.
  • Subjects documented positive for antibodies directed against MuSK.
  • Subjects with corticosteroid (CS) treatment initiated within the last 8 weeks or modified within the last 2 weeks.
  • Subjects with plasma exchange (PLEX) within the last 30 days.
  • Subjects with MG exacerbation attributable to change in medication or infection or evident infection as defined by, but not limited to, the presence of at least one of the following diagnostic features: 1) axillary temperature ≥38°C, 2) positive blood culture of infective microorganism, 3) white blood cell count >12×10^9/L and differential white blood cell count of >10% band neutrophils (>1.2×10^9/L), and 4) pulmonary infiltrate with consolidation on chest X-ray. Alternatively, other signs and symptoms may be considered for the diagnosis of evident infection according to the Investigator's judgement.
  • Subjects with inadequate venous access.
  • Subjects with a history of anaphylactic reactions or severe reactions to any blood-derived product.
  • Subjects with a history of intolerance to any component of the investigational products.
  • Subjects with a documented diagnosis of thrombotic complications to polyclonal IVIG therapy in the past.
  • Subjects with a history of recent (within the last year) myocardial infarction, stroke or uncontrolled hypertension.
  • Subjects who suffer from uncontrolled congestive heart failure, embolism or documented electrocardiogram (ECG) changes indicative of myocardial ischemia or atrial fibrillation.
  • Subjects with current known hyperviscosity or hypercoagulable state.
  • Subjects currently receiving anti-coagulation therapy.
  • Subjects with a history of chronic alcoholism or illicit drug abuse (addiction) in the 12 months preceding the Baseline Visit.
  • Subjects currently receiving, or having received within 3 months prior to the Baseline Visit, any investigational medicinal product or device.
  • Subjects with a known Immunoglobulin A (IgA) deficiency and anti-IgA serum antibodies.
  • Subjects with renal impairment (i.e., serum creatinine exceeds more than 1.5 times the upper limit of normal [ULN] for the expected normal range for the testing laboratory).
  • Subjects with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceeding more than 2.5 times the ULN for the expected normal range for the testing laboratory.
  • Subjects with haemoglobin levels <9 g/dL.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02413580

  Show 31 Study Locations
Sponsors and Collaborators
Grifols Therapeutics LLC

Layout table for additonal information
Responsible Party: Grifols Therapeutics LLC Identifier: NCT02413580     History of Changes
Other Study ID Numbers: GTI1305
First Posted: April 10, 2015    Key Record Dates
Last Update Posted: October 5, 2018
Last Verified: October 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Myasthenia Gravis
Muscle Weakness
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Signs and Symptoms
Autoimmune Diseases of the Nervous System
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs